We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Lung Cancer

Journal Scan / Research · August 09, 2022

Nazartinib for Treatment-Naïve EGFR-Mutant Non–Small Cell Lung Cancer

European Journal of Cancer

 

Additional Info

European Journal of Cancer
Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study
Eur. J. Cancer 2022 Jul 07;172(2022)276-286, DSW Tan, SW Kim, S Ponce Aix, LV Sequist, EF Smit, JCH Yang, T Hida, R Toyozawa, E Felip, J Wolf, C Grohé, NB Leighl, G Riely, X Cui, M Zou, S Ghebremariam, L O'Sullivan-Djentuh, R Belli, M Giovannini, DW Kim

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading